Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients

BACKGROUND: Several clinical studies have demonstrated that continuous administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could provide additional survival benefit for advanced non-small cell lung cancer (NSCLC) patients who had benefited from prior EGFR TKI th...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ling, Wang, Yina, Tang, Yemin, Zeng, Lei, Liu, Junfang, Zeng, Zhu, Liu, Jian, Shi, Peng, Ye, Xianghua, Zhao, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584902/
https://www.ncbi.nlm.nih.gov/pubmed/28894381
http://dx.doi.org/10.2147/OTT.S143569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584902/
https://www.ncbi.nlm.nih.gov/pubmed/28894381
http://dx.doi.org/10.2147/OTT.S143569

Ejemplares similares